RxDoctor Payments DataLook up a doctor →

Yashma Patel, MD

Neurology · Lehi, UTNPI 1700030186

Payments from drug & device makers

$258,872in general payments, 2019–2025

Across 682 payments — averaging $379.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$118K
  • Sanofi$66K
  • E.r. Squibb & Sons, L.L.C.$24K
  • TG Therapeutics, Inc.$17K
  • AstraZeneca$14K
  • Bristol Myers Squibb$9K
  • plus $10K from 32 others

What the payments were for

  • Consulting fees$3,6751%
  • Speaking & faculty fees$201,09280%
  • Travel & lodging$31,93413%
  • Food & beverage$13,8116%
  • Education$1800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,872 in reported general payments places this provider in the 85th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah

Medicare billing

Part B allowed, 2024
$891,406
Medicare patients
72
Services billed
10,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate37$335,283
Avonex (4 Pack)Interferon Beta-1a13$124,805
Kesimpta PenOfatumumab13$101,850
FingolimodFingolimod Hcl51$61,949
Dalfampridine ErDalfampridine92$54,549
Teriflunomide62$41,274
Dimethyl Fumarate32$27,813
MyrbetriqMirabegron15$16,350
LinzessLinaclotide15$13,080
Baclofen157$5,872
Gabapentin110$4,128
Modafinil45$2,341
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine73$1,839
Dantrolene Sodium14$1,441
Cyclobenzaprine Hcl18$700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Avonex (4 Pack)$473$460,08850 claims
AbbVieLinzess$543$13,08015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 157 neurology providers in Utah.

Other neurology in Lehi

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →